BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Han HS, Chang HJ, Hong YS, Kim SY, Lee KS, Jung KH. Epidermal growth factor receptor expression discrepancies in metastatic colorectal cancer patients treated with cetuximab plus irinotecan-based chemotherapy refractory to irinotecan and oxaliplatin. Dis Colon Rectum 2009;52:1144-51; discussion 1152-3. [PMID: 19581859 DOI: 10.1007/DCR.0b013e31819edbf9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Kang MJ, Hong YS, Kim KP, Kim SY, Baek JY, Ryu MH, Lee JL, Chang HM, Kim MJ, Chang HJ. Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status. Invest New Drugs. 2012;30:1607-1613. [PMID: 21706149 DOI: 10.1007/s10637-011-9703-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
2 Krawczyk PA, Kowalski DM. Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer. Contemp Oncol (Pozn). 2014;18:7-16. [PMID: 24876815 DOI: 10.5114/wo.2013.38566] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.2] [Reference Citation Analysis]